Page 5 - Rob Etherington News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: May 17, 2021 International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease Clene anticipates the expansion of disease indications for CNM-Au8 beyond amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis SALT LAKE CITY, May 17, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated...

Clene Reports First Quarter 2021 Operating and Financial Highlights May 11, 2021 07:00 ET | Source: Clene Inc. Clene Inc. Salt Lake City, UNITED STATES Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients Awarded Michael J. Fox Foundation (MJFF) grant to accelerate development of CNM-Au8 as a treatment for Parkinson’s disease Phase 2 RESCUE-ALS trial and Phase 2 target engagement trials in MS and PD remain on tra...

NORTH EAST — Imagine a future where such diseases as Multiple Sclerosis, Lou Gehrig’s Disease and Parkinson’s Disease can be controlled or stopped altogether. It’s more than imagination at Clene Nanomedicine, Inc. in North East where Mark Mortenson and Rob Etherington are leading the charge against these and other insidious degenerative diseases. Mortenson is the founder and CSO and works out of the manufacturing and research and development headquarters on Principio Parkway in North East while Etherington, CEO, works in Salt Lake City, Utah where development takes place. ...

4.5 (32) Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the company’s already patented gold nanocrystals for the treatment of multiple sclerosis (MS). A Notice of Allowance was received by the company. These notices are issued by the U.S. Patent and Trademark Office (USPTO) to indicate an examiner has determined an application merits the requested patent being issued. According to Clene, its gold nanocrystals are free from organic impurities on their surfaces, which makes them “clean” relative to surfa...

Home / Top News / Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis Resulting patent to cover methods of using Clene’s lead candidate CNM-Au8, now in Phase 2 and 3 trials for Multiple Sclerosis (MS) and Amyotrophic lateral sclerosis (ALS) Latest patent allowance adds to Clene’s robust IP estate including over 130 patents issued and pending applications...